Delcath Systems, Inc.
Delcath Systems, Inc. (Nasdaq: DCTH) is an interventional oncology company focused on treating cancers that originate in or spread to the liver. Its HEPZATO KIT combines the chemotherapy drug melphalan with a proprietary hepatic delivery system to deliver treatment to the liver while filtering hepatic venous blood to… From the company’s description.
Over the twelve months to Jun 30, 2026, Delcath Systems, Inc. reported revenue of $95.42M, up 35.8% from a year earlier, and net income of $0.53M. Its operating margin was −1.9%, and operations generated $19.59M in cash. In fiscal 2025, it reported revenue of $85.23M, up 129.1% from fiscal 2024, and net income of $2.70M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Delcath Systems, Inc. does
In the company’s own words
Delcath Systems, Inc. (Nasdaq: DCTH) is an interventional oncology company focused on treating cancers that originate in or spread to the liver. Its HEPZATO KIT combines the chemotherapy drug melphalan with a proprietary hepatic delivery system to deliver treatment to the liver while filtering hepatic venous blood to limit systemic exposure. In the United States, HEPZATO is approved for certain adults with unresectable uveal melanoma liver metastases. In Europe, the device-only CHEMOSAT system is used with melphalan for percutaneous hepatic perfusion to treat a range of liver cancers. Hospitals and cancer centers are the primary treatment settings, with physicians administering the products through an interventional radiology procedure. Delcath operates as one reportable segment and also conducts clinical development focused on additional cancer indications. As of December 31, 2025, 25 U.S. sites were actively treating or preparing to treat patients with HEPZATO, and CHEMOSAT was available at 22 European cancer centers. The company assumed direct responsibility for CHEMOSAT sales and distribution in Europe in 2022. Its website is www.delcath.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- QUEENSBURY, NY
- Fiscal year end
- December
- CIK
- 872912
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Delcath Systems, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Delcath Systems, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Delcath Systems, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Delcath Systems, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Delcath Systems, Inc.'s last four quarterly filings that the numbers alone won't show?”